A systematic review of oral methotrexate for multiple sclerosis

  title={A systematic review of oral methotrexate for multiple sclerosis},
  author={O. Gray and G. McDonnell and R. B. Forbes},
  journal={Multiple Sclerosis},
  pages={507 - 510}
  • O. Gray, G. McDonnell, R. B. Forbes
  • Published 2006
  • Medicine
  • Multiple Sclerosis
  • Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only… CONTINUE READING
    Progressive Multiple Sclerosis
    • 19
    High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis
    • 20
    Chemotherapeutics in the treatment of multiple sclerosis
    • 27
    • PDF
    Therapeutic Approaches to Multiple Sclerosis
    • 7
    Immunotherapy of Multiple Sclerosis
    • 19


    Publications referenced by this paper.
    Methotrexate for multiple sclerosis.
    • 41
    Methotrexate hepatotoxicity: What is the evidence?
    • 17
    Methotrexate: mechanism of action in rheumatoid arthritis.
    • 100
    • PDF
    Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.
    • 59
    • PDF
    The initiation of the autoimmune response in multiple sclerosis
    • 29